Provigil Cost in Louisiana 2026: Generic Modafinil Prices, Medicaid, and Insurance Coverage

Provigil is the brand name for modafinil, a Schedule IV wakefulness-promoting medication approved by the FDA for narcolepsy, obstructive sleep apnea (as an adjunct to primary airway treatment), and shift work disorder. Generic modafinil tablets, manufactured by multiple companies since patent protection ended, are the version most Louisiana patients actually receive and pay for.

The useful question for a Louisiana patient is not "what does Provigil cost" but which of three separate facts applies to their situation: the cash price at a specific pharmacy on a specific day, their own plan's formulary and prior-authorization rule, and whether Louisiana Medicaid currently excludes the drug from its preferred drug list. All three of those facts change independently and none of them can be safely quoted as a fixed 2026 number without checking a current source at the time of use.

The compact answer

Generic modafinil is substantially cheaper than brand-name Provigil at retail pharmacies nationally, and pharmacy discount cards typically lower generic cash prices further; Louisiana-specific dollar figures are not confirmed in the sources available for this article and should be checked directly with a pharmacy or a pricing tool before you rely on them. Modafinil is FDA-approved for narcolepsy, obstructive sleep apnea, and shift work disorder (FDA label), is Schedule IV federally, and its Louisiana Medicaid formulary status and specific commercial insurer prior-authorization rules are date-sensitive facts that require direct verification rather than a one-time published number.

What is established, what is plausible, and what is not established

Established: Modafinil (Provigil) is FDA-approved for narcolepsy, obstructive sleep apnea as adjunct therapy, and shift work disorder, dosed once daily per the FDA label (label PDF). It is a federally scheduled Schedule IV controlled substance. Generic versions have been available since patent exclusivity ended, and generics are reliably far cheaper than the branded product's list price in the broader US market.

Plausible but unproven from the sources here: That a specific dollar figure (a monthly retail average, a specific discount-card price, a specific copay range) holds true across Louisiana pharmacies in 2026. Retail cash prices vary by pharmacy, region, and week, and no Louisiana-specific pricing data source was available to confirm the numbers that circulate in general drug-cost content.

Not established from the sources available: Which named Louisiana Medicaid managed care organizations currently exclude or cover modafinil, the exact prior-authorization criteria used by named commercial insurers in Louisiana, and the current federal telehealth-prescribing rule status for Schedule IV controlled substances. These have all been subject to policy changes and should not be stated as settled facts without checking the current Louisiana Medicaid preferred drug list, the specific insurer's provider portal, and current DEA guidance.

Cash and retail pricing: what you can rely on, and what you must check yourself

Brand-name Provigil carries a high list price compared to generic modafinil; this price gap is a well-documented feature of the branded-versus-generic modafinil market nationally, not specific to Louisiana. Generic modafinil 200 mg tablets are commonly reported as costing well under the brand price at cash-pay pharmacies, and discount coupons from services like GoodRx frequently reduce the price further at participating pharmacies.

What this article cannot responsibly state as fact: a specific average monthly price at Louisiana pharmacies, or a specific dollar range by city. Pharmacy cash pricing for generics shifts frequently and differs by chain, location, and manufacturer supply. Before filling a prescription, check the current price at two or three nearby pharmacies and compare against a discount-card price, since the gap can be meaningful.

The FDA label specifies 200 mg once daily in the morning for narcolepsy and obstructive sleep apnea, and dosing timed before a work shift for shift work disorder (FDA label). This dosing information is stable and does not require date-sensitive verification the way price does.

Louisiana Medicaid coverage: verify before assuming either answer

Whether Louisiana Medicaid or its managed care organizations cover modafinil for any indication is a formulary decision that state Medicaid programs revisit periodically. This article does not have a verified, current source confirming Louisiana's specific 2026 Medicaid formulary status for modafinil, and a confident yes-or-no claim here would be an unsupported exact assertion. Patients enrolled in Louisiana Medicaid managed care should contact their plan's pharmacy benefits department directly, or check the Louisiana Medicaid preferred drug list, before assuming coverage either way.

Separately, professional sleep medicine guidelines have historically supported wakefulness-promoting agents including modafinil as first-line options for narcolepsy-related excessive daytime sleepiness. That is a guideline-level clinical recommendation, distinct from a state Medicaid coverage decision, and one does not guarantee the other.

Commercial insurance: prior authorization is the norm, specifics vary by plan

Commercial insurers commonly place generic modafinil on a mid formulary tier and require prior authorization documenting one of the FDA-approved diagnoses (narcolepsy, obstructive sleep apnea, or shift work disorder), often supported by a sleep study or work-schedule documentation. This general pattern is standard across the pharmaceutical insurance industry and is plausible for Louisiana plans, but the specific insurers, tier placements, and dollar copays that a plan uses in 2026 must come from that plan's current formulary document, not from a generic description. If a prior authorization is denied, an appeal citing the FDA-approved indication and supporting clinical documentation (sleep study results, physician notes) is the standard next step, not a guaranteed one.

Compounded modafinil through 503A pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound a patient-specific preparation when a prescriber documents that a commercially available product does not meet a particular patient's needs, such as a non-standard dose or an inactive-ingredient sensitivity, according to federal compounding regulations. Compounded modafinil is not FDA-approved in the compounded form itself; it relies on a prescriber's individualized clinical judgment rather than an FDA efficacy or safety review of that specific preparation. A patient considering compounding should confirm the pharmacy holds a current, valid state pharmacy license and ask the prescriber to document the specific clinical reason compounding is appropriate rather than simply asking a pharmacy to compound a standard-dose equivalent for cost reasons.

Telehealth prescribing

Telehealth visits can establish a valid prescriber-patient relationship for controlled substance prescribing in many states, and modafinil prescribing through telehealth is common practice nationally. Federal rules governing telehealth prescribing of controlled substances (originating from the Ryan Haight Act and subsequent DEA guidance) have changed multiple times in recent years, including temporary extensions during and after the COVID-19 public health emergency. This article does not have a verified, current source confirming the exact 2026 federal telehealth-prescribing rule status for Schedule IV substances, and readers should confirm current DEA guidance and their state's specific telehealth prescribing requirements before relying on telehealth as a prescribing pathway.

Off-label use and cost

Modafinil is sometimes prescribed off-label for conditions such as ADHD or fatigue in other neurologic conditions. Off-label prescribing is legal, but insurers are far less likely to approve prior authorization for a non-FDA-approved indication, and cash-pay pricing for the same tablet and quantity does not change based on the indication written on the prescription. A prescriber recommending off-label use should discuss the absence of an FDA-approved indication for that use, the evidence quality behind it, and available on-label alternatives.

How modafinil compares to other wakefulness agents

Armodafinil (the R-enantiomer of modafinil, sold generically after Nuvigil's branded exclusivity) is commonly available as a lower-cost generic alternative with a similar mechanism and a longer half-life. Pitolisant (Wakix) and solriamfetol (Sunosi) are newer, FDA-approved narcolepsy medications that occupy substantially higher price tiers than generic modafinil and are typically used after a patient has not tolerated or responded to modafinil. Traditional Schedule II stimulants (amphetamine salts, methylphenidate) are inexpensive generics but carry a different abuse-potential classification and side-effect profile, making them a different pharmacological choice rather than a direct substitute purely on cost.

Verification checklist: what's stable vs. what you must confirm before paying

Use this to separate facts you can trust as written from facts that change and need a fresh check.

Stable facts (federal/clinical, unlikely to change month to month):

• Modafinil's FDA-approved indications: narcolepsy, obstructive sleep apnea (adjunct), shift work disorder.
• Standard FDA-labeled dosing: 200 mg once daily, timing adjusted for shift work disorder.
• Modafinil's federal Schedule IV controlled-substance status.
• The existence of generic modafinil as a lower-cost alternative to brand Provigil.
• The legal basis for 503A pharmacy compounding under federal law when a prescriber documents patient-specific need.

Date-sensitive facts you must verify before relying on them (check within days of use, not months):

• Current cash price for generic modafinil at a specific Louisiana pharmacy.
• Current discount-card price (GoodRx, RxSaver, or similar) at that same pharmacy.
• Whether Louisiana Medicaid or a specific managed care organization currently covers modafinil, and under what exception process.
• Your specific commercial insurer's current formulary tier, prior-authorization criteria, and copay for modafinil.
• Current federal and Louisiana-specific rules on telehealth prescribing of Schedule IV controlled substances.
• Whether a specific patient assistance program or manufacturer copay card is currently active and what its eligibility rules are.

How to verify: Call the pharmacy directly for cash price, check the discount-card app at the point of sale, call the number on the insurance card and ask specifically about modafinil's tier and prior-authorization requirement, and check the state Medicaid preferred drug list or call the MCO's pharmacy benefits line for coverage status. Treat any published number older than a few weeks as a starting estimate, not a quote.

A note on a removed claim

An earlier version of this content included a quoted statement attributed to a named physician about modafinil's clinical positioning. That quotation could not be verified against a citable, attributable source, so it has been removed rather than presented as fact. Readers should not treat unattributed or unverifiable physician quotes in drug-cost content as clinical guidance.

When to seek in-person or urgent care instead of relying on cost-shopping

Cost and coverage logistics should not delay evaluation if a patient has new or worsening excessive daytime sleepiness affecting driving safety, chest pain, irregular heartbeat, signs of a serious skin reaction (rash, blistering, mucosal involvement), or mood changes including new suicidal thoughts after starting modafinil. Those situations call for prompt medical evaluation regardless of where or how affordably the medication was obtained.